Novartis in Society Integrated Report 2024 This report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create sustainable value for diverse sta
The Novartis in Society Integrated Report provides an overview our business, strategy and performance, and describes how we create sustainable value for stakeholders and society. Annual Report 2024 The Annual Report 2024, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overv...
Novartis in Society Integrated Report(9 MB) All babies deserve appropriate treatment Despite the tremendous progress made in combating malaria, one child still dies from the disease every minute. Novartis is committed to contributing to the WHO’s target of reducing malaria-related child mortality by...
1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 47 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this R...
Novartis in Society Integrated Report(9 MB) All babies deserve appropriate treatment Despite the tremendous progress made in combating malaria, one child still dies from the disease every minute. Novartis is committed to contributing to the WHO’s target of reducing malaria-related child mortality by...
1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 47 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Rele...
To aid in comparability, the prior year free cash flow amounts have been revised to conform with the new free cash flow definition. See page 49 of the Condensed Financial Report. nm = not meaningful 3 Strategy update Our focus During 2023, Novartis completed our transformation into a "...
3. Strengthening foundations: Unleashing the power of our people, scaling data science and technology and continuing to build trust with society. Financials Following the September 15, 2023, shareholder approval of the spin-off of Sandoz, Novartis reported its consolidated financial statements as "...